What is IPCL and how does it correct vision problems?

IPCL is an implantable contact lens that corrects myopia and astigmatism by inserting a small lens into the eye.

What material is used to manufacture the IPCL lens?

It uses an acrylic polymer material primarily composed of HEMA, which is widely used in cataract intraocular lenses.

Why is the IPCL treatment considered highly reversible compared to LASIK?

Unlike LASIK, IPCL does not involve shaving the cornea, meaning the inserted lens can be removed in the future.

When did IPCL receive regulatory approval and launch in Japan?

IPCL obtained regulatory approval in April 2025 and was subsequently launched in September of the same year.

What percentage of the survey subjects were interested in implantable contact lenses?

About 70% (71.9%) of the survey subjects were interested in it as a treatment method.

AI News NQ Analysis

Survey on Awareness of Implantable Contact Lenses (Phakic Posterior Chamber Lenses) Among Men and Women in Their 20s-40s with Vision of 0.1 or Less

NQ Score 50/100

AI Summary (NQ-processed)

At Working Co., Ltd., the Japanese distributor of "IPCL®," an implantable contact lens approved by the Ministry of Health, Labour and Welfare in April 2025, conducted a survey on implantable contact lenses among men and women in their 20s to 40s nationwide. The survey found that over 70% of respondents were aware of the treatment, with nearly the same percentage expressing interest. The primary drivers of interest were the inconvenience and ongoing cost of glasses and traditional contact lenses, while the main deterrents were fear of surgery and safety concerns. Interest was notably higher among women in their 20s and 30s.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is IPCL and how does it correct vision problems?: A: IPCL is an implantable contact lens that corrects myopia and astigmatism by inserting a small lens into the eye.
Q: What material is used to manufacture the IPCL lens?: A: It uses an acrylic polymer material primarily composed of HEMA, which is widely used in cataract intraocular lenses.
Q: Why is the IPCL treatment considered highly reversible compared to LASIK?: A: Unlike LASIK, IPCL does not involve shaving the cornea, meaning the inserted lens can be removed in the future.
Q: When did IPCL receive regulatory approval and launch in Japan?: A: IPCL obtained regulatory approval in April 2025 and was subsequently launched in September of the same year.
Q: What percentage of the survey subjects were interested in implantable contact lenses?: A: About 70% (71.9%) of the survey subjects were interested in it as a treatment method.